Stay updated on Vemurafenib & Cobimetinib in BRAF V600E Craniopharyngioma Clinical Trial
Sign up to get notified when there's something new on the Vemurafenib & Cobimetinib in BRAF V600E Craniopharyngioma Clinical Trial page.

Latest updates to the Vemurafenib & Cobimetinib in BRAF V600E Craniopharyngioma Clinical Trial page
- Check5 days agoChange DetectedAdded a Locations section listing participating sites by state and updated to Revision: v3.3.3; removed the prior state location entries and the HHS Vulnerability Disclosure link.SummaryDifference1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedPublications section updated to clarify entries are automatically filled from PubMed and to reflect revision v3.3.2.SummaryDifference0.1%

- Check41 days agoChange DetectedThe page header no longer shows the government funding status banner. This is a non-critical banner removal that does not alter the study details presented.SummaryDifference0.2%

- Check55 days agoChange DetectedThe two screenshots display minor formatting tweaks and small textual updates to the Study Details page, with no changes to core study information such as title, objectives, eligibility criteria, primary outcomes, or listed locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check84 days agoChange DetectedIntroducing version v3.2.0 and a government-operating-status notice; removing the older v3.1.0 reference.SummaryDifference2%

- Check91 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No changes to core content, pricing, or stock are evident.SummaryDifference0.1%

Stay in the know with updates to Vemurafenib & Cobimetinib in BRAF V600E Craniopharyngioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Vemurafenib & Cobimetinib in BRAF V600E Craniopharyngioma Clinical Trial page.